News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Johnson & Johnson (JNJ)'s Janssen Biotech Inc. and Molecular Partners AG Expand Agreement to Immunological Diseases in Deal Worth $800 Million



12/8/2011 6:55:49 AM

ZURICH-SCHLIEREN, Switzerland--(BUSINESS WIRE)--Molecular Partners AG today announced that it has entered into a strategic research collaboration and option agreement with Janssen Biotech, Inc. to research, discover and develop DARPinĀ® products for the treatment of immunological diseases. The collaboration and expansion of its current agreement with the company and its affiliates aims to explore a defined set of targets, including the use of multispecific DARPinsĀ®, to address diseases where continued unmet needs for effective treatment options continue to exist.

Under the agreement, Molecular Partners and Janssen Biotech will collaborate on research of DARPins to selected targets. During the research phase, Janssen Biotech has the right to exercise four options to exclusively license DARPin(R)-based products. Upon execution of each option, Janssen Biotech will be solely responsible for all clinical development, manufacturing, and commercialization activities. Molecular Partners has an option to co-develop one product on a global basis.

Molecular Partners will receive significant upfront fees, license payments and research funding as part of an innovative agreement, as well as development and sales milestones of up to $200 million for each option. Upon commercialization, Molecular Partners will be entitled to a tiered and up to double-digit royalty on worldwide net sales.

"We are thrilled about entering into this broader alliance with Janssen Biotech as an expansion of our current agreement, which is a significant effort to build and expand our internal and external immunology pipeline. We see the enabling power of the DARPin(R) platform as a compound engine for us and our partners to generate pioneering multi-specific compounds delivering true patient benefit," said Christian Zahnd, Ph.D., Chief Executive Officer of Molecular Partners. "The strategic value of this deal is the collaborative approach with a multi-disciplinary team of world-class scientists, under which Molecular Partners expands its position of strength as a biopharmaceutical company pioneering innovative protein therapeutics, while retaining rights to develop novel assets not optioned by Janssen Biotech during the research collaboration."

SOURCE: Molecular Partners

College Hill Life Sciences

Nicole Yost, Daniel Gooch

Tel: +44 (0) 20 7866 7855 or 7866

nicole.yost@collegehill.com

daniel.gooch@collegehill.com

or

For Molecular Partners:

Dr. Patrick Amstutz, CBO

Tel: +41 (0) 44 755 77 00

patrick.amstutz@molecularpartners.com




comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES